Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications
复制标题
DOI：
10.1046/j.1365-2141.2003.04589.x
复制
发表时间：
2003-10-01
影响因子：
6.5
通讯作者：
Kawase, I
中科院分区：
文献类型：
--
作者：
Saeki, Y;Mima, T;Kawase, I
在这项研究中，我们研究了骨髓瘤细胞中骨桥蛋白（OPN）的产生和多发性骨髓瘤（MM）患者血浆OPN水平。我们通过免疫细胞化学和酶联免疫吸附试验（ELISA）评估了骨髓细胞（BMC）中OPN的产生。我们还通过逆转录聚合酶链反应（RT-PCR）和蛋白质印迹法评估了各种B细胞恶性细胞系（包括三种骨髓瘤细胞系）中OPN的产生。此外，我们还通过ELISA法测定了30例MM患者、21例意义不明的单克隆丙种球蛋白病（MGUS）患者和30例健康志愿者的血浆OPN浓度。因此，在免疫细胞化学研究中，在明显MM患者的BMCs中检测到丰富的OPN，而在其他血液疾病（包括MGUS）患者的BMCs中未检测到OPN。从显性MM患者培养的BMCs产生更多的OPN比那些从闷烧MM或MGUS患者。骨髓瘤细胞系自发产生OPN。MM患者血浆OPN水平显著高于MGUS患者和健康志愿者（P
In this study, we examined osteopontin (OPN) production in myeloma cells and plasma OPN levels in multiple myeloma (MM) patients. We assessed OPN production in bone marrow cells (BMCs) by immunocytochemistry and enzyme-linked immunosorbent assay (ELISA). We also assessed OPN production in various B-cell malignant cell lines, including three myeloma cell lines by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting. In addition, we measured plasma OPN concentrations by ELISA in 30 MM patients, 21 monoclonal gammopathy of undetermined significance (MGUS) patients and 30 healthy volunteers. As a result, in an immunocytochemical study, abundant OPN was detected in BMCs from overt MM patients, whereas no OPN was detected in BMCs from patients with other haematological diseases, including MGUS. Cultured BMCs from overt MM patients produced more OPN than those from patients with either smouldering MM or MGUS. Myeloma cell lines spontaneously produced OPN. Plasma OPN levels of MM patients were significantly higher than those of MGUS patients and healthy volunteers (P